Holen Sie sich die Stockscreener-App
0.9851
1.35%
0.0131
Renovorx Inc Aktie (RNXT) Neueste Nachrichten
RenovoRx (RNXT) Advances Phase III Trial for Pancreatic Cancer T - GuruFocus
Johns Hopkins Medicine Initiates Patient Enrollment For Renovorx'S Ongoing Phase III Tiger-Pac Clinical Trial - marketscreener.com
Johns Hopkins Medicine Accelerates RenovoRx's Breakthrough Pancreatic Cancer Trial Progress - Stock Titan
RenovoRx (NASDAQ:RNXT) Price Target Raised to $11.00 at Ascendiant Capital Markets - Defense World
RenovoRx Reports Initial Revenue and Clinical Trial Progress - MSN
RenovoRx CMO Makes Bold Stock Purchase! - TipRanks
RenovoRx chief medical officer Agah Ramtin buys $13,500 in common stock - Investing.com Australia
RenovoRx chief medical officer Agah Ramtin buys $13,500 in stock - Investing.com Australia
RenovoRx chief medical officer Agah Ramtin buys $13,500 in stock By Investing.com - Investing.com Canada
RenovoRx chief medical officer Agah Ramtin buys $13,500 in common stock By Investing.com - Investing.com South Africa
RenovoRx ramps up production of FDA-cleared RenovoCath By Investing.com - Investing.com India
New Jersey Patients Receiving First-of-Its-Kind Catheter Based Pancreatic Cancer Treatment | Newswise - Newswise
RenovoRx CEO Shaun Bagai acquires $6,821 in common stock - Investing.com Australia
RenovoRx CEO Shaun Bagai acquires $6,821 in common stock By Investing.com - Investing.com Canada
RenovoRx Increases U.S. Production of RenovoCath® Devices to Meet Growing Demand from Oncology Community - BioSpace
RenovoRx ramps up production of FDA-cleared RenovoCath - Investing.com
Renovorx Increases U.S. Production Of Renovocath Devices To Meet Growing Demand From Oncology Community - marketscreener.com
Medical Device Maker RenovoRx Eyes $400M Market With Surging RenovoCath Demand - Stock Titan
RenovoRx CMO Makes Bold Stock Purchase - TipRanks
RenovoRx chief medical officer Agah Ramtin buys $16,000 in stock By Investing.com - Investing.com India
RenovoRx chief medical officer Agah Ramtin buys $16,000 in stock - Investing.com
RenovoRx CMO Agah Ramtin purchases $24,399 in common stock By Investing.com - Investing.com India
Top Executives Make Bold Moves with RenovoRx Stock Purchases! - TipRanks
RenovoRx VP controller Ronald Kocak acquires over $10,000 in stock By Investing.com - Investing.com Canada
RenovoRx VP controller Ronald Kocak acquires over $10,000 in stock - Investing.com Australia
RenovoRx Executives Increase Their Holdings - TradingView
RenovoRx CMO Agah Ramtin purchases $24,399 in common stock - Investing.com
RenovoRx CEO Shaun Bagai acquires $8,300 in common stock By Investing.com - Investing.com Canada
RenovoRx CEO Shaun Bagai acquires $8,300 in common stock - Investing.com
Renovorx director Marton Laurence buys $10,218 in common stock By Investing.com - Investing.com UK
RenovoRx CMO Makes a Bold Move with Major Stock Purchase - TipRanks
RenovoRx Executives Increase Stake in Company - TradingView
Renovorx director Marton Laurence buys $10,218 in common stock - Investing.com
Renovorx chief medical officer Agah Ramtin buys $21,840 in shares - Investing.com Australia
Renovorx chief medical officer Agah Ramtin buys $21,840 in shares By Investing.com - Investing.com Canada
RenovoRx CEO Shaun Bagai purchases $8,300 in company stock By Investing.com - Investing.com Canada
RenovoRx CEO Shaun Bagai purchases $8,300 in company stock - Investing.com
RenovoRx stock hits 52-week low at $0.77 amid market challenges - Investing.com Australia
RenovoRx stock hits 52-week low at $0.77 amid market challenges By Investing.com - Investing.com South Africa
HC Wainwright Reaffirms “Buy” Rating for RenovoRx (NASDAQ:RNXT) - Defense World
H.C. Wainwright maintains Buy rating on RenovoRx stock By Investing.com - Investing.com South Africa
1.36%
0.60%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):